UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2005

Novogen Limited
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 27 June, 2005  By /s/Ronald Lea Erratt Company Secretary

ASX & MEDIA RELEASE
27 JUNE 2005

NOVOGEN RECEIVES THREE GRANTED PATENTS IN AUSTRALIA COVERING
ISOFLAVONE HEALTH SUPPLEMENTS.

Novogen Limited has received the grant of three health supplement
patents in Australia.

The patents cover tablets or capsules containing any two
of the four main isoflavones, biochanin, formononetin, daidzein
and genistein, all of which have been associated with a range
of health benefits including management of menopause symptoms,
improved cardiovascular and bone health and improved prostate
function in men.

Novogen's health products Promensil and Trinovin benefit directly
from the issue of theses patents, and the Company will now be
seeking the protection in the market place that the patents allow.
The term of the patents is until year 2013.

Similar patents have been issued to the Company in Canada and
the United States, where Novogen is engaged in patent enforcement
and licensing negotiations.

The company sources isoflavones from red clover which has all
four isoflavones, and the patents also cover the two isoflavones
derived from soy.

Promensil is the leading natural menopause isoflavone supplement
in Australia.  Trinovin is the leading isoflavone supplement
for prostate health in men.  Both products are available Australia
wide in pharmacies, health food stores and major supermarkets.
Worldwide sales of Novogen isoflavone consumer products last year
were over A$14 million.

Novogen has an international business in the research and
development of drugs derived from its phenolic technology platform.
The Company manages its research and development programs utilising
the expertise and clinical research capabilities of universities
and hospitals in Australia, the US and other key international
locations.  The Novogen group of companies includes the listed
subsidiary Marshall Edwards Inc. (Nasdaq: MSHL LSE-AIM:MSH).

More information on the Novogen Group can be found at
www.novogen.com and www.marshalledwardsinc.com.

Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995.  You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Novogen Limited, + 61.2.9878 0088